Patents by Inventor Jochen Knolle

Jochen Knolle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6586442
    Abstract: A compound of the formula wherein the substituents are as defined in the specification and its pharmaceutically acceptable salts and it prodrug useful for treating osteoporosis.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: July 1, 2003
    Inventors: Denis Carniato, Jean-Francois Gourvest, Jochen Knolle, Anurschirwan Peyman, Sarah C. Bodary, Thomas R. Gadek
  • Patent number: 6566366
    Abstract: Compounds of the formula and salts thereof wherein the substituents are defined as in accordance with the specification useful for the treatment of tumor growth, osteoporosis, inflammation and cardiovascular disorders.
    Type: Grant
    Filed: March 6, 2001
    Date of Patent: May 20, 2003
    Assignees: Aventis Pharma Deutschland GmbH, Genentech, Inc.
    Inventors: Karl-Heinz Scheunemann, Jochen Knolle, Amuschirwan Peyman, David William Will, Denis Carniato, Jean-Francois Gourvest, Thomas Gadek, Robert McDowell, Sarah Catherine Bodary, Robert Andrew Cuthbertson
  • Publication number: 20030050314
    Abstract: There are described cycloalkyl derivatives of the formula (I)
    Type: Application
    Filed: May 10, 2002
    Publication date: March 13, 2003
    Applicant: Aventis Pharma S.A.
    Inventors: Volkmar Wehner, Jochen Knolle, Hans Ulrich Stilz, Jean-Francois Gourvest, Denis Carniato, Thomas Richard Gadek, Robert McDowell, Robert Maurice Pitti, Sarah Catherine Bodary
  • Publication number: 20030027807
    Abstract: The present invention relates to compounds of the formula I
    Type: Application
    Filed: May 13, 2002
    Publication date: February 6, 2003
    Applicant: Genentech, Inc. and Hoechst Aktiengesellschaft
    Inventors: Volkmar Wehner, Hans Ulrich Stilz, Anuschirwan Peyman, Jochen Knolle, Jean-Marie Ruxer, Denis Carniato, Jean-Michel Lefrancois, Thomas Richard Gadek, Robert McDowell
  • Patent number: 6500815
    Abstract: The invention concerns compounds of formula (I) wherein: X, Y, R1, R2, Z, G are as defined in the description, the methods for preparing them and the intermediates in said method, their use as medicine and the pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: December 31, 2002
    Assignees: Aventis Pharma S.A., Genentech
    Inventors: Denis Carniato, Thomas R. Gadek, Jochen Knolle, Jean-Francois Gourvest, Anurschirwan Peyman, Sarah C. Bodary
  • Publication number: 20020187976
    Abstract: A compound of the formula 1
    Type: Application
    Filed: June 26, 2002
    Publication date: December 12, 2002
    Applicant: Aventis Pharma S.A.
    Inventors: Denis Carniato, Jean-Francois Gourvest, Jochen Knolle, Anurschirwan Peyman, Sarah Bodary, Thomas R. Gadek
  • Patent number: 6492356
    Abstract: The present invention relates to acylguanidine derivatives of formula (I) in which R1, R2, R4, R5, R6, A, m and n have the meanings indicated in the patent claims, their physiologically tolerable salts and their prodrugs. The compounds of formula (I) are valuable pharmaceutical active ingredients. They are vitronectin receptor antagonists and inhibitors of bone resorption by osteoclasts and are suitable, for example, for the therapy or prophylaxis of diseases which are caused at least partially by an undesired extend of bone resorption, for example of osteoporosis. The invention furthermore relates to processes for the preparation of compounds of formula (I), their use, in particular as pharmaceutical active ingredients, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: December 10, 2002
    Assignees: Aventis Pharma Deutschland GmbH, Genentech, Inc.
    Inventors: Anuschirwan Peyman, Jochen Knolle, Gerhard Breipohl, Karl-Heinz Scheunemann, Denis Carniato, Jean-Francois Gourvest, Thomas Gadek, Robert McDowell, Sarah Catherine Bodary, Robert Andrew Cuthbertson, Napoleane Ferrara
  • Patent number: 6465650
    Abstract: The invention provides a processes for the preparation of a compound of Formula I, or a salt thereof wherein PG is a urethane- or trityl-type protective group; X is NH, O, or S; Y is CH2, O, or NH; and B′ is a base customary in nucleotide chemistry. The processes include reacting a compound of Formula (II) with a compound of Formula (III) a compound of Formula (V) B′—CH2—CO—R2  (V), a monohaloacetic acid derivative in a suitable solvent with an auxiliary base, or a compound of Formula (VII) B′—CH2—CO—R3  (VII), and converting the resulting compounds to that of Formula I.
    Type: Grant
    Filed: February 18, 2000
    Date of Patent: October 15, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Breipohl, Eugen Uhlmann, Jochen Knolle
  • Patent number: 6458801
    Abstract: A compound of the formula wherein the substituents are as defined in the specification and its pharmaceutically acceptable salts and its prodrug useful for treating osteoporosis.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: October 1, 2002
    Assignees: Aventis Pharma S.A., Genentech, Inc.
    Inventors: Denis Carniato, Thomas R. Gadek, Jean-Francois Gourvest, Jochen Knolle, Anurschirwan Peyman, Sarah C. Bodary
  • Patent number: 6459001
    Abstract: The subject of the invention is the products of formula (I): in which R1, R2, R3, R4, R5 and G are as defined in the description, the dotted lines represent an optional second bond, as well as the addition salts with acids and bases and the esters, their preparation process and the intermediates of this process, their use as medicines and the pharmaceutical compositions containing them.
    Type: Grant
    Filed: January 25, 2001
    Date of Patent: October 1, 2002
    Assignees: Aventis Pharma S.A., Genetech
    Inventors: Serge Bernard, Denis Carniato, Jean-Francois Gourvest, Jean-Georges Teutsch, Jochen Knolle, Hans-Ulrich Stilz, Volkmar Wehner, Sarah C. Bodary, Thomas R. Gadek, Robert S. McDowell, Robert M. Pitti
  • Publication number: 20020119999
    Abstract: The present invention relates to 5-membered ring heterocycles of the formula I, 1
    Type: Application
    Filed: February 21, 2002
    Publication date: August 29, 2002
    Applicant: HOECHST AKTIENGESELLSCHAFT
    Inventors: Volkmar Wehner, Jochen Knolle, Hans Ulrich Stilz, Denis Carniato, Jean-Francois Gourvest, Tom Gadek, Robert McDowell
  • Patent number: 6399620
    Abstract: There are described cycloalkyl derivatives of the formula (I) R1—Y—A—B—D—E—F—G  (I) in which R1, Y, A, B, D, E, F and G have the meaning indicated herein, their preparation and their use as medicaments. The compounds according to the invention can be used as vitronectin receptor antagonists and as inhibitors of bone resorption.
    Type: Grant
    Filed: June 29, 2000
    Date of Patent: June 4, 2002
    Assignee: Aventis Pharma S.A.
    Inventors: Volkmar Wehner, Jochen Knolle, Hans Ulrich Stilz, Jean-Francois Gourvest, Denis Carniato, Thomas Richard Gadek, Robert McDowell, Robert Maurice Pitti, Sarah Catherine Bodary
  • Publication number: 20020065271
    Abstract: Sulfonamide derivatives, their physiologically tolerable salts and their prodrugs according to the present invention are vitronectin receptor antagonists and inhibitors of cell adhesion, as well as inhibit bone resorption by osteoclasts. These derivatives, salts and prodrugs are pharmaceutically active compounds useful in the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. Processes for the preparation of the sulfonamide derivatives according to the present invention, the use of these derivatives as pharmaceutically active ingredients, and pharmaceutical preparations comprising these derivatives also are disclosed.
    Type: Application
    Filed: October 9, 2001
    Publication date: May 30, 2002
    Inventors: Anuschirwan Peyman, David William Will, Jochen Knolle, Karlheinz Scheunemann, Denis Carniato, Jean-Francois Gourvest, Thomas R. Gadek, Robert Mcdowell, Sarah Catherine Bodary, Robert Andrew Cuthbertson
  • Patent number: 6391904
    Abstract: A compound of the formula where the substituents are defined in the specification and its pharmaceutically acceptable salts and prodrugs thereof useful as antagonists of vitronectin receptors.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: May 21, 2002
    Assignees: Aventis Pharma S.A., Genentech, Inc.
    Inventors: Denis Carniato, Jean-Francois Gourvest, Jean-Marie Ruxer, Jochen Knolle, Anurschirwan Peyman, Sarah C. Bodary, Thomas R. Gadek
  • Patent number: 6387895
    Abstract: The present invention relates to compounds of the formula I A—B—D—E—F—G  (I) in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.
    Type: Grant
    Filed: February 6, 2001
    Date of Patent: May 14, 2002
    Assignees: Hoechst Aktiengesellschaft, Genentech, Inc.
    Inventors: Volkmar Wehner, Hans Ulrich Stilz, Anuschirwan Peyman, Jochen Knolle, Jean-Marie Ruxer, Denis Carniato, Jean-Michel Lefrancois, Thomas Richard Gadek, Robert McDowell
  • Patent number: 6344439
    Abstract: The object is to provide a promoting agent for bone formation, a therapeutic method for bone formation and a process for preparing a promoting agent for bone formation. A promoting agent for bone formation which comprises at least one of kistrin, echstatin, a peptide or polypeptide containing the amino acid sequence ArgGlyAsp in the molecule such as a peptide represented by Gly-Arg-Gly-Asp-Ser or a compound represented by the following general formula (IX) and so on, as well as a biologically acceptable salt thereof wherein R16 represents —N(R20)2 (R20 represents a hydrogen atom or a C1-C4 alkyl group), R17 represents a hydrogen atom or a C1-C4 alkyl group, R18 represents a hydrogen atom, a C1-C4 alkyl group and so on, R19 represents OH, NH2 and so on, Y represents —NH—, —O— or a direct bond, a represents 1-3, b represents 1 or 2, c represents 0 or 1 and d represents 0 or 1.
    Type: Grant
    Filed: July 26, 2000
    Date of Patent: February 5, 2002
    Assignee: Aventis Pharma S.A.
    Inventors: Kazuyuki Kitamura, Osamu Komiyama, Mizuho Inazu, Roland Baron, Thomas R. Gadek, Jochen Knolle, Hans-Ulrich Stilz, Volkmar Wehner, Robert S. McDowell
  • Patent number: 6340679
    Abstract: The present invention relates to acylguanidine derivatives of the formula I in which R1, R2, R4, Ar, X and n have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of the formula I are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion. They inhibit, for example, bone resorption by osteoclasts and are suitable for the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example osteoporosis. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceutical preparations, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: January 22, 2002
    Assignees: Aventis Pharma Deutschland GmbH, Genentech, Inc.
    Inventors: Anuschirwan Peyman, Jochen Knolle, Karl-Heinz Scheunemann, David William Will, Denis Carniato, Jean-Francois Gourvest, Thomas R. Gadek, Sarah Catherine Bodary
  • Patent number: 6339082
    Abstract: A compound selected from the group consisting of a compound of the formula wherein the substituents are defined as set forth in the specification and its salts with non-toxic pharmaceutically acceptable acids and bases useful for treating loss of bone matrix.
    Type: Grant
    Filed: June 29, 2000
    Date of Patent: January 15, 2002
    Assignees: Aventis Pharma S.A., Genetech, Inc.
    Inventors: Denis Carniato, Thomas R. Gadek, Jean-Francois Gourvest, Jochen Knolle, Robert S. McDowell, Anurschirwan Peyman
  • Patent number: 6316595
    Abstract: The invention provides compounds and processes for synthesis of peptide nucleic acids (PNA). The compounds include temporary amino protecting groups that are base-labile, and protection groups for the exocyclic amino function of the nucleotide base that is compatible with the base-labile amino protecting group. Cleavage of an oligomer comprising these compounds from a solid support can be achieved using weak or medium strength acids.
    Type: Grant
    Filed: February 1, 2000
    Date of Patent: November 13, 2001
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Breipohl, Eugen Uhlmann, Jochen Knolle
  • Patent number: 6313119
    Abstract: Sulfonamide derivatives, their physiologically tolerable salts and their prodrugs according to the present invention are vitronectin receptor antagonists and inhibitors of cell adhesion, as well as inhibit bone resorption by osteoclasts. These derivatives, salts and prodrugs are pharmaceutically active compounds useful in the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. Processes for the preparation of the sulfonamide derivatives according to the present invention, the use of these derivatives as pharmaceutically active ingredients, and pharmaceutical preparations comprising these derivatives also are disclosed.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: November 6, 2001
    Assignees: Adventis Pharma Deutschland GmbH, Genentech, Inc.
    Inventors: Anuschirwan Peyman, David William Will, Jochen Knolle, Karlheinz Scheunemann, Denis Carniato, Jean-Francois Gourvest, Thomas R. Gadek, Robert McDowell, Sarah Catherine Bodary, Robert Andrew Cuthbertson